ESMO Congress 2022 reported pooled survival analysis of the MONALEESA‐2, ‐3, and ‐7 trials in HR‐positive, HER2‐negative breast cancer patients with visceral metastases, including those with liver metastases. The gene discussed is ERBB2; the disease is breast cancer.